The Early Pathogenesis of Diabetic Retinopathy and Its Attenuation by Sodium–Glucose Transporter 2 Inhibitors
Diabetes · 01.07.2024 · 73 (7) · 1153-1166
DOI: 10.2337/db22-0970 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, online erschienen am 12.04.2024. Verfasst von Mayumi Yamato und 3 weiteren Autor:innen. Beteiligte Einrichtung: Physical Chemistry for Life Science Laboratory, Faculty of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan. Hauptthemen laut MEDLINE: Diabetic Retinopathy, Sodium-Glucose Transporter 2 Inhibitors, Microglia, Diabetes Mellitus, Experimental. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Astellas Pharma Inc., AMED-CREST grant, JSPS KAKENHI grants.
Abstract (Originalsprache)
The early pathogenetic mechanism of diabetic retinopathy (DR) and its treatment remain unclear. Therefore, we used streptozotocin-induced diabetic mice to investigate the early pathogenic alterations in DR and the protective effect of sodium–glucose cotransporter 2 (SGLT2) inhibitors against these alterations. Retinal vascular leakage was assessed by dextran fluorescence angiography. Retinal thickness and vascular leakage were increased 2 and 4 weeks after onset of diabetes, respectively. Immunostaining showed that morphological change of microglia (amoeboid form) was observed at 2 weeks. Subsequently, increased angiopoietin-2 expression, simultaneous loss of pericytes and endothelial cells, decreased vessel density, retinal hypoxia, and increased vascular endothelial growth factor (VEGF)-A/VEGF receptor system occurred at 4 weeks. SGLT2 inhibitors (luseogliflozin and ipragliflozin) had a significant protective effect on retinal vascular leakage and retinal thickness at a low dose that did not show glucose-lowering effects. Furthermore, both inhibitors at this dose attenuated microglia morphological changes and these early pathogenic alterations in DR. In vitro study showed both inhibitors attenuated the lipopolysaccharide-induced activation of primary microglia, along with morphological changes toward an inactive form, suggesting the direct inhibitory effect of SGLT2 inhibitors on microglia. In summary, SGLT2 inhibitors may directly prevent early pathogenic mechanisms, thereby potentially playing a role in preventing DR. Article Highlights
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Physical Chemistry for Life Science Laboratory, Faculty of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.
- Fukuoka City Health Promotion Support Center, Fukuoka City Medical Association, Fukuoka, Japan.
ORCID-Profile: Mayumi Yamato, Toyoshi Inoguchi
Förderung
- Astellas Pharma Inc.
- AMED-CREST grant
- JSPS KAKENHI grants
- Taisho Pharmaceutical Co., Ltd.
- Takeda Science Foundation
Zitieren
APA
Yamato, M., Kato, N., Yamada, K. I., & Inoguchi, T. (2024). The Early Pathogenesis of Diabetic Retinopathy and Its Attenuation by Sodium–Glucose Transporter 2 Inhibitors. Diabetes, 73(7), 1153-1166. https://doi.org/10.2337/db22-0970
Vancouver
Yamato M, Kato N, Yamada KI, Inoguchi T. The Early Pathogenesis of Diabetic Retinopathy and Its Attenuation by Sodium–Glucose Transporter 2 Inhibitors. Diabetes. 2024;73(7):1153-1166. doi:10.2337/db22-0970
BibTeX
@article{Yamato2024,
author = {Yamato, Mayumi and Kato, Nao and Yamada, Ken-Ichi and Inoguchi, Toyoshi},
title = {The Early Pathogenesis of Diabetic Retinopathy and Its Attenuation by Sodium–Glucose Transporter 2 Inhibitors},
journal = {Diabetes},
year = {2024},
volume = {73},
number = {7},
pages = {1153--1166},
doi = {10.2337/db22-0970}
}
EUVIMED